Here are three things to know:
1. CartiHeal’s proprietary implant is designed for joint surface lesion treatment.
2. The first two U.S. patients were enrolled in the Agili-C Investigational Device Exemption pivotal study.
3. In Europe and Israel, 80 patients have been enrolled and treated in the study, which aims to demonstrate Agili-C’s superiority over microfracture and debridement to treat cartilage or osteochondral defects in the knee.
More articles on devices:
Life Spine reports device revenue growth: 3 details
25%+ of hip arthroscopy patients still get opioids 3 months after surgery: 5 things to know
DePuy Synthes, Medtronic, NuVasive & more: 9 device company notes
